NexImmune (NEXI) 10-Q2022 Q3 Quarterly report

Filed: 14 Nov 22, 4:38pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: alternative, appeal, attention, attract, Aug, bid, bill, breadth, Bulletin, calendar, case, climate, combating, consecutive, cure, delisted, delisting, dispose, divert, fee, harm, harmed, Hearing, history, inclusion, inefficiency, injectable, intention, knowledge, Kristi, largest, letter, long, lose, motivate, nanoparticle, Nasdaq, national, NEXI, notice, notification, optimize, OTC, panel, pipeline, prescription, President, realign, realigned, realignment, reallocate, regain, regained, restructuring, resume, slight, symbol, taxable, transfer, turnover, unexpected, workforce

Removed: acute, AML, human, leukemia, MM, myeloid

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

NEXI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of NexImmune, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge that:

The Quarterly Report for the period ended September 30, 2021 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 14, 2022	By:	/s/ Kristi Jones
		Kristi Jones
		Chief Executive Officer (Principal Executive Officer)